Published in Cancer Weekly, May 24th, 1999
Cancer remains one of the most important public health concerns, noted researchers P. Dematos and colleagues from Duke University, North Carolina ("Monitoring Antitumor Immune Response During Immunotherapy of Cancer - Why and How'," Biodrugs, April 1999;11(4):239-247).
"Despite recent therapeutic developments, conventional therapies have provided only limited success in the management of patients with advanced disease," wrote Dematos et al. "The recent discovery of tumor-associated antigens has led to a strong interest in...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.